342 related articles for article (PubMed ID: 36531457)
1. Sex- and region-specific associations of skeletal muscle mass with metabolic dysfunction-associated fatty liver disease.
Xiao P; Liang P; Gao P; Wu J
Front Endocrinol (Lausanne); 2022; 13():1057261. PubMed ID: 36531457
[TBL] [Abstract][Full Text] [Related]
2. Association of low muscle strength with metabolic dysfunction-associated fatty liver disease: A nationwide study.
Lee GB; Huh Y; Lee SH; Han B; Kim YH; Kim DH; Kim SM; Choi YS; Cho KH; Nam GE
World J Gastroenterol; 2023 Dec; 29(45):5962-5973. PubMed ID: 38131000
[TBL] [Abstract][Full Text] [Related]
3. The relationship between skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease subtypes in middle-aged and elderly population: a single-center retrospective study.
Xing M; Ni Y; Zhang Y; Zhao X; Yu X
Front Nutr; 2023; 10():1246157. PubMed ID: 38024359
[TBL] [Abstract][Full Text] [Related]
4. Low skeletal muscle mass is associated with non-alcoholic fatty liver disease in Korean adults: the Fifth Korea National Health and Nutrition Examination Survey.
Kim HY; Kim CW; Park CH; Choi JY; Han K; Merchant AT; Park YM
Hepatobiliary Pancreat Dis Int; 2016 Feb; 15(1):39-47. PubMed ID: 26818542
[TBL] [Abstract][Full Text] [Related]
5. The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations.
Feng Z; Zhao F; Wang Z; Tang X; Xie Y; Qiu L
BMC Gastroenterol; 2024 Mar; 24(1):111. PubMed ID: 38491346
[TBL] [Abstract][Full Text] [Related]
6. Association between depression and metabolic dysfunction-associated fatty liver disease/significant fibrosis.
Kim D; Dennis BB; Cholankeril G; Ahmed A
J Affect Disord; 2023 May; 329():184-191. PubMed ID: 36841305
[TBL] [Abstract][Full Text] [Related]
7. A dynamic association between myosteatosis and liver stiffness: Results from a prospective interventional study in obese patients.
Nachit M; Lanthier N; Rodriguez J; Neyrinck AM; Cani PD; Bindels LB; Hiel S; Pachikian BD; Trefois P; Thissen JP; Delzenne NM
JHEP Rep; 2021 Aug; 3(4):100323. PubMed ID: 34355155
[TBL] [Abstract][Full Text] [Related]
8. Impact of skeletal muscle mass evaluating methods on severity of metabolic associated fatty liver disease in non-elderly adults.
Zhou T; Ye J; Lin Y; Wang W; Feng S; Zhuo S; Zhong B
Br J Nutr; 2023 Oct; 130(8):1373-1384. PubMed ID: 36896599
[TBL] [Abstract][Full Text] [Related]
9. Prediction of MAFLD and NAFLD using different screening indexes: A cross-sectional study in U.S. adults.
Peng H; Pan L; Ran S; Wang M; Huang S; Zhao M; Cao Z; Yao Z; Xu L; Yang Q; Lv W
Front Endocrinol (Lausanne); 2023; 14():1083032. PubMed ID: 36742412
[TBL] [Abstract][Full Text] [Related]
10. Associations between muscle mass, strength, and performance and non-alcoholic fatty liver disease.
Rigor J; Vasconcelos R; Lopes R; Moreira T; Barata P; Martins-Mendes D
Minerva Gastroenterol (Torino); 2023 Sep; 69(3):374-381. PubMed ID: 35343663
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive prediction nomogram for predicting significant fibrosis in patients with metabolic-associated fatty liver disease: a cross-sectional study.
Zhang F; Han Y; Mao Y; Zheng G; Liu L; Li W
Ann Med; 2024 Dec; 56(1):2337739. PubMed ID: 38574396
[TBL] [Abstract][Full Text] [Related]
12. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population.
Seo JY; Cho EJ; Kim MJ; Kwak MS; Yang JI; Chung SJ; Yim JY; Yoon JW; Chung GE
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2953-2960. PubMed ID: 36222309
[TBL] [Abstract][Full Text] [Related]
13. The association of triglyceride-glucose-waist circumference with metabolic associated fatty liver disease and the severity of liver steatosis and fibrosis in American adults: a population-based study.
Wu Z; Huang K; Bao S; Zhang X; Li J; Kong W; Shi Y; Xie Y
Scand J Gastroenterol; 2024 May; 59(5):561-569. PubMed ID: 38235548
[TBL] [Abstract][Full Text] [Related]
14. Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease.
Han E; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Kim SU
Gut Liver; 2022 Sep; 16(5):786-797. PubMed ID: 35321955
[TBL] [Abstract][Full Text] [Related]
15. Associations of Serum Iron Status with MAFLD and Liver Fibrosis in the USA: a Nationwide Cross-Section Study.
Yu G; Liu L; Qin T; Luo Y; Song C; Chen X; Duan H; Jiang Y; Zeng H; Wan H; Shen J
Biol Trace Elem Res; 2024 Jan; 202(1):87-98. PubMed ID: 37079265
[TBL] [Abstract][Full Text] [Related]
16. Associations of depression score with metabolic dysfunction-associated fatty liver disease and liver fibrosis.
Cai H; Zhang R; Zhao C; Wang Y; Tu X; Duan W
J Affect Disord; 2023 Aug; 334():332-336. PubMed ID: 37142003
[TBL] [Abstract][Full Text] [Related]
17. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease.
Chun HS; Kim MN; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1168-1178. PubMed ID: 34337887
[TBL] [Abstract][Full Text] [Related]
18. MAFLD and risk of CKD.
Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
[TBL] [Abstract][Full Text] [Related]
19. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011).
Lee YH; Jung KS; Kim SU; Yoon HJ; Yun YJ; Lee BW; Kang ES; Han KH; Lee HC; Cha BS
J Hepatol; 2015 Aug; 63(2):486-93. PubMed ID: 25772036
[TBL] [Abstract][Full Text] [Related]
20. Validation of non-invasive indicators in the screening of metabolic dysfunction-associated fatty liver disease: a cross-sectional study among Uighurs in rural Xinjiang.
Guo Y; Hu Y; Yang J; Ma R; Zhang X; Guo H; Wang X; Li Y; Peng X; Zhang S; He J; Guo S
Eur J Med Res; 2023 Dec; 28(1):555. PubMed ID: 38042816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
